Plasmid DNA purification has come a long way since Herbert Boyer and Stanley N. Cohen's experiments in the early 1970s. Molecular biology is now dominated by the various ways recombinant DNA and RNA can be manipulated, and purification techniques have evolved to meet this demand. In sharp contrast to the complicated, labor-intensive efforts that were needed in previous decades to extract even a small amount of DNA, there are now numerous easy-to-use DIY kits available that enable researchers to obtain the DNA they need.
Plasmids are essential for the development of viral vectors used to manufacture novel gene therapies and viral vaccines. Aldevron is supporting the innovation of drug developers in this space by providing standardized royalty-free, bulk AAV helper and lentiviral packaging plasmids for research and GMP production.
Aldevron, Sanford Health, North Dakota State University highlight advances in rare disease treatment
Area organizations Aldevron, Sanford Health, and North Dakota State University (NDSU) have joined forces to bring together a special event titled, "From the Valley to the Mountain: The RARE Impact of the Red River Valley," on Wednesday, April 11 from 5:30-8 p.m. at Aldevron corporate headquarters, 4837 Amber Valley Parkway, Fargo N.D. The evening will start with refreshments, a Meet and Greet, and a silent auction, followed by leaders in science and medicine from the Red River Valley sharing their contributions toward advancing gene therapy and rare disease research efforts around the world.
When we talk about One Health, just what do we mean? On its own, the phrase can be interpreted to mean many things, but for what we do in the biotechnology field, it encompasses human and animal health and disease, along with related environmental and epidemiological components. Essentially, it defines how people and animals interact with, and within, our shared environments, especially in reference to health and developing treatments for diseases.
By Mark Osborn, Ph.D., Minnesota Stem Cell Institute, University of Minnesota
CRISPR/Cas9 is a vital part of our research at the University of Minnesota and the Cas9 recombinant protein, used at high concentration, has allowed for highly efficient modification of T-cells.
By introducing a Cas9 nuclease guide RNA complex (RNP), we target a specific spot in the genome, where the nuclease cuts the DNA. The DNA break is repaired in one of two ways: homologous recombination, which is high-fidelity, or non-homologous endjoining (NHEJ), which is more error-prone.